StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
SHANMUGA.BO$36.72+0.00%
Fair $36.72+0.0%

SHANMUGA.BO

SHANMUGA.BO

Healthcare / Medical Care FacilitiesBSE

$36.72

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $36.72Fund rank 27/100 · Data gapFallback financials|
SA 47/C
F-Score: 5/9
Margin Compression

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 22%

FCF escenarios

weak_data · normalized FCF $-59.7M · quality 65.3/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 26/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

47/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Operating margin has declined for 3 consecutive years
Thesis & Journal · SHANMUGA.BOLocal privado en este navegador · SHANMUGA.BO
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$500M

P/E

11.9x

↓

EV/EBITDA

6.2x

↓

ROE

9.9%

↑

Gross Margin

52.9%

↑

Debt/Equity

0.16

↓
52-Week Range$37
$34$57

TradingView lightweight chart

SHANMUGA.BO price, volumen y niveles de valoración

Último $37.00Periodo -27.9%
Fair value: $36.72

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

+6.4%

FCF CAGR

—

FCF margin

-17.2%

FCF / Net income

-1.94x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $474.4M · net income $42.1M · FCF $-81.5M

2023-FY → 2026-FY

Gross margin

52.9%+0.8% pts

Operating margin

11.5%-5.5% pts

Net margin

8.9%-3.2% pts

FCF margin

-17.2%-3.7% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$474.4M$474.4M$478.5M$430.4M$393.4M
Net Income$42.1M$42.1M$42.1M$52.5M$47.6M
EBITDA$89.1M$89.1M$84.7M$88.5M$74.3M
EPS——4.033.863.50
Gross Margin52.9%52.9%51.3%53.1%52.2%
Operating Margin11.5%11.5%12.7%16.9%17.1%
Net Margin8.9%8.9%8.8%12.2%12.1%
Balance Sheet
Debt/Equity0.160.160.190.530.65
Current Ratio2.222.22———
Cash Flow
Free Cash Flow$-81.5M$-81.5M$-59.7M$-19.3M$-53.2M
Returns
ROE9.9%9.9%10.6%30.6%40.3%
Valuation
P/E11.8811.888.25——
EV/EBITDA6.156.153.51——
P/B1.181.180.87——
Growth & Yield
Revenue Growth-0.9%-0.9%11.2%9.4%—
EPS Growth——4.5%10.2%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -5.7%

Total return

-5.7%

Start / end P/E

n/dx → n/dx

EPS bridge

4.03 → n/d

Residual

-5.7%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-5.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.